171 related articles for article (PubMed ID: 20819888)
1. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
2. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
3. Licensing drugs for diabetes.
Lehman R; Yudkin JS; Krumholz H
BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
[No Abstract] [Full Text] [Related]
4. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
5. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
6. Major US consumer group asks FDA to ban drug for diabetes.
Tanne JH
BMJ; 2008 Nov; 337():a2401. PubMed ID: 18987042
[No Abstract] [Full Text] [Related]
7. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
8. Insiders criticise FDA's decision not to withdraw rosiglitazone.
Cohen D
BMJ; 2010 Sep; 341():c5333. PubMed ID: 20880925
[No Abstract] [Full Text] [Related]
9. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
10. Avandia panel member may be investigated for possible conflicts of interest.
Tanne JH
BMJ; 2010 Aug; 341():c4083. PubMed ID: 20682621
[No Abstract] [Full Text] [Related]
11. Rosiglitazone and the need for a new drug safety agency.
Garattini S; Bertele' V
BMJ; 2010 Oct; 341():c5506. PubMed ID: 20926483
[No Abstract] [Full Text] [Related]
12. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
13. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
14. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
15. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
16. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
17. FDA places greater restrictions on access to rosiglitazone.
BMJ; 2010 Sep; 341():c5287. PubMed ID: 20870699
[No Abstract] [Full Text] [Related]
18. FDA committees say keep rosiglitazone available but increase warnings.
Tanne JH
BMJ; 2007 Aug; 335(7613):223. PubMed ID: 17673743
[No Abstract] [Full Text] [Related]
19. The Yin and the Yang of CV risks in patients with diabetes.
Dangi-Garimella S
Am J Manag Care; 2014 May; 20(8 Spec No.):E6. PubMed ID: 25617925
[No Abstract] [Full Text] [Related]
20. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
[Next] [New Search]